Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares By Investing.com

Joana Goncalves, Chief Medical Officer at Oruka Therapeutics, Inc. (), sold a total of 7,947 shares of common stock on September 15, 2026, for a combined value of approximately $734,144. The sale comes as the biotech company’s stock trades at $92.20, up more than 518% over the past year, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value—placing it among companies on the most overvalued list. These transactions followed the exercise of employee stock options and warrants.

The majority of the sales, totaling 7,000 shares, were executed through a Rule 10b5-1 trading plan established on September 19, 2025. These shares were sold at weighted average prices ranging from $91.0962 to $94.2172, generating approximately $643,507.

An additional 947 shares were sold to cover tax withholding obligations arising in connection with the vesting of restricted stock units. These shares were sold at a price of $95.71, amounting to approximately $90,637.

Prior to these sales, Ms. Goncalves acquired 7,000 shares of Oruka Therapeutics common stock by exercising employee stock options and warrants on the same date, September 15, 2026. The exercised options and warrants had prices ranging from $6.84 to $7.8, with the total value of these acquisitions being approximately $51,240. The option and warrant vest as to 1/4 of the underlying shares on April 18, 2025, and as to 1/48 of the underlying shares monthly from April 18, 2025.

Following these reported transactions, Ms. Goncalves directly holds 31,771 shares of Oruka Therapeutics common stock. She also beneficially owns 193,563 employee stock options and 164,992 employee warrants. Analysts maintain a bullish outlook with price targets ranging from $117 to $200, while the company carries a market capitalization of $6.35 billion despite remaining unprofitable.

In other recent news, Oruka Therapeutics has been the subject of several analyst updates and corporate developments. UBS raised its price target for Oruka Therapeutics to $130, maintaining a Buy rating, based on positive expectations for the company’s upcoming 28-week efficacy data readout. This data is anticipated to show higher efficacy compared to previous results, as well as to Skyrizi at the same timepoint. H.C. Wainwright also reiterated a Buy rating on Oruka Therapeutics with a $120 price target, emphasizing confidence in the company’s prospects. Additionally, Oruka Therapeutics announced the appointment of Todd Edwards as Chief Commercial Officer, bringing over 25 years of commercial leadership experience in immunology and dermatology. In related industry news, AbbVie announced its acquisition of Apogee Therapeutics, focusing on candidates for inflammatory and immunological diseases. This acquisition may have implications for the competitive landscape in which Oruka Therapeutics operates. These developments reflect ongoing interest and activity around Oruka Therapeutics in the investment community.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.